Vistagen Therapeutics - VTGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 452.33%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.44
▲ +0.09 (2.69%)

This chart shows the closing price for VTGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vistagen Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VTGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTGN

Analyst Price Target is $19.00
▲ +452.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Vistagen Therapeutics in the last 3 months. The average price target is $19.00, with a high forecast of $30.00 and a low forecast of $12.00. The average price target represents a 452.33% upside from the last price of $3.44.

This chart shows the closing price for VTGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Vistagen Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2023Jefferies Financial GroupUpgradeHold ➝ Buy$15.00Low
12/4/2023William BlairReiterated RatingOutperformLow
11/14/2023Stifel NicolausInitiated CoverageBuy$12.00Low
9/5/2023Maxim GroupReiterated RatingBuy ➝ Buy$30.00Low
8/7/2023Maxim GroupUpgradeHold ➝ Buy$30.00Low
7/26/2022Maxim GroupDowngradeBuy ➝ HoldLow
7/22/2022Robert W. BairdDowngradeOutperform ➝ NeutralLow
7/22/2022Jefferies Financial GroupDowngradeBuy ➝ HoldLow
7/22/2022William BlairDowngradeOutperform ➝ Market PerformLow
10/17/2021Robert W. BairdInitiated CoverageBuy$270.00High
8/15/2021Robert W. BairdReiterated RatingBuy$270.00Medium
5/19/2021Robert W. BairdInitiated CoverageOutperform$270.00High
2/18/2021Jefferies Financial GroupInitiated CoverageBuy$180.00High
1/4/2021William BlairUpgradeMarket Perform ➝ OutperformN/A
12/22/2020Maxim GroupBoost Target$90.00 ➝ $150.00Low
10/8/2020AegisInitiated CoverageBuy$180.00Low
8/11/2020Maxim GroupReiterated RatingBuy$90.00High
6/26/2020Maxim GroupReiterated RatingBuy$30.00Medium
5/29/2020Maxim GroupInitiated CoverageBuy$30.00High
4/29/2020Maxim GroupInitiated CoverageBuy$30.00Low
12/2/2019Chardan CapitalReiterated RatingNeutralHigh
11/14/2019William BlairDowngradeOutperform ➝ Market PerformHigh
11/3/2019Chardan CapitalReiterated RatingHold$21.00Low
10/15/2019Maxim GroupSet TargetBuy$120.00N/A
10/9/2019William BlairReiterated RatingBuyN/A
10/8/2019Maxim GroupSet TargetBuy$120.00Low
8/28/2019William BlairInitiated CoverageOutperformHigh
7/29/2019Chardan CapitalReiterated RatingNeutralHigh
7/22/2019Chardan CapitalDowngradeBuy ➝ Neutral$660.00 ➝ $21.00High
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
11/27/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/26/2024
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/25/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
4/25/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Vistagen Therapeutics logo
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.44
Low: $3.32
High: $3.48

50 Day Range

MA: $4.22
Low: $3.22
High: $4.83

52 Week Range

Now: $3.44
Low: $1.62
High: $24.71

Volume

20,415 shs

Average Volume

232,530 shs

Market Capitalization

$92.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Vistagen Therapeutics?

The following sell-side analysts have issued research reports on Vistagen Therapeutics in the last twelve months: Jefferies Financial Group Inc., Maxim Group, Stifel Nicolaus, and William Blair.
View the latest analyst ratings for VTGN.

What is the current price target for Vistagen Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Vistagen Therapeutics in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 452.3%. Maxim Group has the highest price target set, predicting VTGN will reach $30.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $12.00 for Vistagen Therapeutics in the next year.
View the latest price targets for VTGN.

What is the current consensus analyst rating for Vistagen Therapeutics?

Vistagen Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VTGN will outperform the market and that investors should add to their positions of Vistagen Therapeutics.
View the latest ratings for VTGN.

What other companies compete with Vistagen Therapeutics?

How do I contact Vistagen Therapeutics' investor relations team?

Vistagen Therapeutics' physical mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 577-3600 and its investor relations email address is [email protected]. The official website for Vistagen Therapeutics is www.vistagen.com. Learn More about contacing Vistagen Therapeutics investor relations.